Martin Karlík1, Peter Valkovič1, Viera Hančinová2, Lucia Krížová2, Ľubomíra Tóthová3, Peter Celec4. 1. 2nd Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 2. Department of Neurology, Slovak Medical University, Bratislava, Slovakia. 3. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Center for Molecular Medicine, Slovak Academy of Sciences, Bratislava, Slovakia. Electronic address: tothova.lubomira@gmail.com. 4. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Center for Molecular Medicine, Slovak Academy of Sciences, Bratislava, Slovakia; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia.
Abstract
BACKROUND: Oxidative stress plays a role in multiple sclerosis. Saliva can be potentially used to study the disease progression or treatment, because of its non-invasiveness and easy collection. But studies on saliva and multiple sclerosis are missing. The aim of this study was to compare the concentrations of salivary oxidative stress markers in patients and healthy controls. OBJECTIVE: Whole saliva and blood samples were collected from 29 patients and 29 healthy controls. Samples were collected during relapse, after corticosteroid therapy, and after three months. Markers of oxidative, carbonyl stress and antioxidant status were measured. RESULTS: In plasma, thiobarbituric acid reacting substances, advanced oxidation protein products and fructosamine were significantly higher in patients compared to controls (by 271%, 46% and 24%, respectively; p<0.01). Total antioxidant capacity in plasma was lower by 20% (p<0.01) in patients versus controls. In saliva, higher levels of thiobarbituric acid reacting substances and advanced glycation end-products were observed in patients when compared to controls (by 51% and 49% respectively; p<0.01). Ferric reducing ability was reduced by 38% (p<0.05) in patients with multiple sclerosis. CONCLUSION: According to our knowledge, this is the first report showing higher markers of oxidative stress and lower antioxidant status in patients with multiple sclerosis in saliva.
BACKROUND: Oxidative stress plays a role in multiple sclerosis. Saliva can be potentially used to study the disease progression or treatment, because of its non-invasiveness and easy collection. But studies on saliva and multiple sclerosis are missing. The aim of this study was to compare the concentrations of salivary oxidative stress markers in patients and healthy controls. OBJECTIVE: Whole saliva and blood samples were collected from 29 patients and 29 healthy controls. Samples were collected during relapse, after corticosteroid therapy, and after three months. Markers of oxidative, carbonyl stress and antioxidant status were measured. RESULTS: In plasma, thiobarbituric acid reacting substances, advanced oxidation protein products and fructosamine were significantly higher in patients compared to controls (by 271%, 46% and 24%, respectively; p<0.01). Total antioxidant capacity in plasma was lower by 20% (p<0.01) in patients versus controls. In saliva, higher levels of thiobarbituric acid reacting substances and advanced glycation end-products were observed in patients when compared to controls (by 51% and 49% respectively; p<0.01). Ferric reducing ability was reduced by 38% (p<0.05) in patients with multiple sclerosis. CONCLUSION: According to our knowledge, this is the first report showing higher markers of oxidative stress and lower antioxidant status in patients with multiple sclerosis in saliva.
Authors: In-Young Choi; Phil Lee; Peter Adany; Abbey J Hughes; Scott Belliston; Douglas R Denney; Sharon G Lynch Journal: Mult Scler Date: 2017-06-01 Impact factor: 6.312
Authors: Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala Journal: J Interv Card Electrophysiol Date: 2021-03-10 Impact factor: 1.900